Recent Finacing
Recent Raise
Dracen develops a platform of proprietary glutamine antagonists discovered at Johns Hopkins and IOCB Prague, targeting tumor immunometabolism with preclinical efficacy and plans for clinical trials and PD-1/PD-L1 combinations.
